Skip to main content
Browse Subject Areas

Click through the PLOS taxonomy to find articles in your field.

For more information about PLOS Subject Areas, click here.

  • Loading metrics

Functional characterization of GABAA receptor-mediated modulation of cortical neuron network activity in microelectrode array recordings

  • Benjamin M. Bader,

    Roles Conceptualization, Data curation, Formal analysis, Writing – review & editing

    Affiliation NeuroProof GmbH, Friedrich-Barnewitz-Str. 4, Rostock, Germany

  • Anne Steder,

    Roles Data curation, Formal analysis

    Affiliation NeuroProof GmbH, Friedrich-Barnewitz-Str. 4, Rostock, Germany

  • Anders Bue Klein,

    Roles Data curation, Formal analysis

    Affiliation Department of Drug Design and Pharmacology, Faculty of Health and Medical Sciences, University of Copenhagen, Universitetsparken 2, Copenhagen Ø, Denmark

  • Bente Frølund,

    Roles Resources

    Affiliation Department of Drug Design and Pharmacology, Faculty of Health and Medical Sciences, University of Copenhagen, Universitetsparken 2, Copenhagen Ø, Denmark

  • Olaf H. U. Schroeder,

    Roles Conceptualization

    Affiliation NeuroProof GmbH, Friedrich-Barnewitz-Str. 4, Rostock, Germany

  • Anders A. Jensen

    Roles Conceptualization, Formal analysis, Funding acquisition, Writing – original draft, Writing – review & editing

    Affiliation Department of Drug Design and Pharmacology, Faculty of Health and Medical Sciences, University of Copenhagen, Universitetsparken 2, Copenhagen Ø, Denmark


The numerous γ-aminobutyric acid type A receptor (GABAAR) subtypes are differentially expressed and mediate distinct functions at neuronal level. In this study we have investigated GABAAR-mediated modulation of the spontaneous activity patterns of primary neuronal networks from murine frontal cortex by characterizing the effects induced by a wide selection of pharmacological tools at a plethora of activity parameters in microelectrode array (MEA) recordings. The basic characteristics of the primary cortical neurons used in the recordings were studied in some detail, and the expression levels of various GABAAR subunits were investigated by western blotting and RT-qPCR. In the MEA recordings, the pan-GABAAR agonist muscimol and the GABABR agonist baclofen were observed to mediate phenotypically distinct changes in cortical network activity. Selective augmentation of αβγ GABAAR signaling by diazepam and of δ-containing GABAAR (δ-GABAAR) signaling by DS1 produced pronounced changes in the majority of the activity parameters, both drugs mediating similar patterns of activity changes as muscimol. The apparent importance of δ-GABAAR signaling for network activity was largely corroborated by the effects induced by the functionally selective δ-GABAAR agonists THIP and Thio-THIP, whereas the δ-GABAAR selective potentiator DS2 only mediated modest effects on network activity, even when co-applied with low THIP concentrations. Interestingly, diazepam exhibited dramatically right-shifted concentration-response relationships at many of the activity parameters when co-applied with a trace concentration of DS1 compared to when applied alone. In contrast, the potencies and efficacies displayed by DS1 at the networks were not substantially altered by the concomitant presence of diazepam. In conclusion, the holistic nature of the information extractable from the MEA recordings offers interesting insights into the contributions of various GABAAR subtypes/subgroups to cortical network activity and the putative functional interplay between these receptors in these neurons.


γ-Aminobutyric acid (GABA), the major inhibitory neurotransmitter in the central nervous system (CNS), exerts its physiological effects through two distinct receptor families, the GABAA and GABAB receptors (GABAARs and GABABRs, respectively) [13]. The GABAARs are a highly heterogenous family of ligand-gated anion-selective channels, and the abundance of GABAergic neurons and the key roles played by GABAARs in the CNS means that the receptors hold considerable potential as targets for therapeutic invention in a wide range of central disorders. Thus, GABAARs are targeted by drugs used in the clinical treatment of sleeping disorders, anxiety and epilepsy, and they are pursued as putative drug targets in numerous neurodegenerative, cognitive and psychiatric disorders [49]. However, the widespread expression of GABAARs and the multiple functions governed by different receptor subtypes are also believed to be at the root of many of the adverse effects associated with the fairly non-selective GABAAR-based therapeutics currently available. Thus, an increased understanding of the physiological functions mediated by different GABAARs could potentially form the basis for development of more efficient and/or safer drugs [2, 3].

The GABAAR is a pentameric membrane-bound subunit complex, and the heterogeneity of native GABAAR populations arises from the existence of a total of 19 subunits (α16, β13, γ13, δ, ε, π, θ, ρ13) that assemble into a plethora of receptor subtypes differentially expressed throughout the CNS [2, 3]. The molecular diversity of GABAARs is also considerable at the neuronal level. The synaptic GABAARs expressed at postsynaptic densities that mediate “phasic inhibition” are predominantly αβγ receptors composed of α1, α2 and/or α3, β2 and/or β3, and γ subunits (typically γ2) [2, 3]. In addition to these receptors, activation of perisynaptic or extrasynaptic GABAARs by low levels of ambient GABA gives rise to a persistent “tonic inhibition” that regulates the excitability and the firing mode of the neuron [10, 11]. The α4βδ receptors constitute the major extrasynaptic GABAAR in most brain regions, in particular in the forebrain, with α6βδ GABAARs being the predominant extrasynaptic receptors in cerebellum and with α5βγ2 and α1βδ receptors being important mediators of tonic inhibition in hippocampal and neocortical pyramidal cells and interneurons, respectively [2, 1013]. These different locations of the receptors at the neuronal body mean that they mediate different contributions to synaptic transmission and neuronal activity. Both overall excitability and output of the specific neuron and global neuronal network activity is regulated by a multitude of mechanisms, and a component of the homeostatic plasticity of GABAergic synapses seems to arise from yet poorly elucidated interactions between phasic and tonic inhibition [14].

The respective roles of different GABAAR subtypes in GABAergic neurotransmission have most often been studied in electrophysiological recordings of phasic and tonic currents in cultured neurons or brain slices from rodents. While these recordings provide detailed insight into the GABAARs expressed in specific neurons and their importance for neuronal activity and synaptic transmission, the recordings do not necessarily elucidate the overall effects of GABAAR-mediated signaling at entire neuronal networks. The use of microelectrode arrays (MEAs) enables the recordings of extracellular action potentials of cultured neurons and thus elucidatation of the activity characteristics of neuronal networks. For more than 20 years, this technological platform has been used for studying neurotoxic effects of compounds and toxins [1517] but also in studies investigating the functional modes of action of ligands [1722]. In the present study, we have applied this technology to study the effects induced by a broad selection of pharmacological tools characterized by different GABAAR subtype-selectivity profiles at the spontaneous activity patterns of primary neuronal networks from murine frontal cortex, and in this way we have elucidated GABAAR-mediated effects on neuronal activity in a more holistic manner than possible by conventional slice and patch-clamp electrophysiology.

Materials and methods


THIP (4,5,6,7-tetrahydroisoxazolo[5,4-c]pyridin-3-ol, also termed gaboxadol) and Thio-THIP (4,5,6,7-tetrahydroisothiazolo[5,4-c]pyridin-3-ol) were synthesized in-house essentially as previously described [23, 24]. DS1 (4-chloro-N-[6,8-dibromo-2-(2-thienyl)imidazo[1,2-a]pyridine-3-yl benzamide), DS2 (4-chloro-N-[2-(2-thienyl)imidazo[1,2-a]pyridine-3-yl benzamide) and flunitrazepam were obtained from Sigma-Aldrich (Copenhagen, Denmark), Tocris Cookson (Bristol, UK) and Roche (Mannheim, Germany), respectively, and diazepam, clonazepam, zolpidem, muscimol and baclofen were purchased from Sigma-Aldrich (Munich, Germany). The in vitro pharmacological properties of the respective drugs are given in Table 1 and will be outlined given in more detail in Results.

Table 1. Pharmacological properties of the drugs used in the present study.


All neural tissue from animal were prepared according to the EU Directive 2010/63/EU on the protection of animals used for scientific purposes (certification file number 7221.3–2). In this study no animal experiments were performed in accordance with the German Animal Protection §7/2 (Tierschutzgesetz). Time-pregnant animals were purchased and shipped by a licensed animal supplier Charles River, Germany. Animals were stored in a separate room for less than 24 hours after arrival in their transport boxes including food and water equivalent. Animal storage is supervised by an animal welfare officer at NeuroProof GmbH, Germany. Short-term storage of animals in transport boxes is in agreement with Directive (EG) Nr. 1/2005 (Animal safety during transport). The mice were sacrificed by cervical dislocation according to the German Animal Protection Act §4.

Primary cell cultures

Pre-frontal cortex tissue was harvested from embryonic day 15/16 chr:NMRI mice (Charles River). Tissue was dissociated by enzymatic digestion (133,3 Kunitz units/ml DNase; 10 Units/ml papain) and mechanical trituration, counted, vitality controlled, and plated in DMEM containing 5% fetal bovine serum and 5% horse serum on poly-D-lysine- and laminin-coated microelectrode array (MEA) neurochips with 2x32 passive electrodes for two independent experiments per MEA (Center for Network NeuroScience, University of North Texas, Denton, TX). The density of plating was 4,000 cells per mm2. Cultures on the MEA chips were incubated at 37°C in a 10% CO2 atmosphere until ready for use, typically four weeks after seeding. Culture media was replenished twice a week with DMEM containing 10% horse serum. The developing co-cultures were treated with the mitosis inhibitor 5-fluoro-2'-deoxyuridine (25μM) and uridine (63 μM) for 48 h on day 5 after seeding to prevent further glial proliferation. After 4 weeks in culture, the activity pattern stabilizes and is composed of one coordinated main burst pattern with several coordinated sub-patterns [18, 19, 2529]. In this study cultures between 28 and 35 days in vitro were used.

Multichannel recordings and data analysis

Extracellular recordings were performed using a computer-controlled 64-channel MEA workstation acquisition system (Plexon, Inc., Dallas, TX), where temperature control of 37°C and stable pH of 7.4 (10% CO2) enabled stable recording and cumulative concentration-response determinations for periods longer than 10 h. Recordings were performed as previously reported using a computer-controlled 64-channel MEA workstation acquisition system (Plexon, Inc., Dallas, TX) providing amplification, filtering and digital signal processing of MEA signals [20]. The total system gain used was 10 K with a simultaneous 40 kHz sampling rate, and the signals routinely recorded by these neurochips are located in the range of 15–800 μV [20]. The neuronal networks were acutely treated with a series of accumulating increasing concentrations of the test compound (maximum assay concentration of DMSO: 0.1%), and the recordings were performed over time periodes of 8–9 h. The network response (spike rate) was observed online. Each of the test compound concentrations was applied and incubated for at least 60 minutes of which a stable phase of 30 minutes was used for data analysis, and real time unit separation and spike identification were performed in real time as previously described. The multichannel signal acquisition system delivered single neuron spike data including action potential waveforms. Spike identification and separation were accomplished using a template-matching algorithm in real time [20]. This permitted the simultaneous extracellular recording of action potentials from a maximum of 256 neurons per MEA, thus 128 per experiment. The action potentials, or “spikes”, were recorded as spike trains; they are clustered in so-called bursts. Bursts were quantitatively described via direct spike train analysis using the program NeuroEXplorer (Plexon Inc., Dallas, TX) and NPWaveX (NeuroProof GmbH, Rostock, Germany). Bursts were defined by the beginning and end of short spike events. Maximum spike intervals defining the start of a burst were adjusted from 50 to 150 ms, and maximum intervals to end a burst from 100 to 300 ms [20]. Bursts definition and high content analysis of the network activity patterns provided a multiparametric description characterizing the activity changes in four defined categories: “General Activity”, “Burst Structure”, “Oscillatory Behaviour” and “Synchronicity” (presented in detail in section 3.1.2). Unless otherwise specified, the parameters for each experiment and each experimental treatment were normalized to the corresponding values of the native reference activity. Our minimal acceptance criteria for active MEA networks was 6 bursting neurons in a network as this allows a network analysis using the synchronicity measures. In average 25 active units (from 32 electrodes) were recorded per network, with peaks of up to 100 units per network. The data from the recordings with DS2 (alone) has been published previously [22], whereas the other data presented in this study has not.

In the figures in this study, heat map presentations depicting the changes induced by the various pharmacological tools in 40 of the 204 activity parameters are given together with concentration-response curves for 10 selected activity parameters. The definitions of some of these activity parameters have been presented in a recent publication [30], and the definitions of all 40 parameters shown in the figures are given in S1 Table. In brief: spike rate: number of spikes per second, averaged over all spike trains recorded per 60 s bin; burst rate: number of bursts per second, a measure for burstiness of units averaged over all units recorded per 60 s bin; burst duration: mean lengths of bursts (in ms) based on inter-spike interval (ISI) method; burst amplitude: bursts are mathematically superimposed with an integral function defined by spike peak density in bursts and number of spikes, and burst amplitude is the peak amplitude of the integrated burst reflecting the fraction of the bursts with highest spike density; spike rate SD and burst rate SD: SD of spike and burst rate, respectively, across 60 s bins, indicating the variability of spikiness and burstiness of units within temporal episodes; spike rate CVnet and burst rate CVnet: coefficient of variation of spike and burst rate, respectively, reflecting spatial variation of spike and burst rate over the network during experimental episodes; Syn All: average distance of bursts within a population burst from population burst center, a measure for the strength of synchronicity of a network; Spike Simplex; spike trains are divided into timeframes of 1 ms bin-size, and within these bins different units within the network generate spikes. All units exhibiting a spike are defined as one simplex, and the outcome of the quantity of all simplex is the “Spike Simplex”, a measure for connectivity and complexity in neuronal network (higher values reflect higher synchronicity among neurons). Distribution of “Simplex events” are not distributed as in an in silico-generated poisson spike train. A detailed analysis shows that different units are involved in “Simplex events”. Doublete analyses (separation of units with identical origin) showed that the probability of doublets is below 1%.

Statistical analysis

We used a minimum of 2 MEAs per animal preparation, and data were produced from cultures of at least 3 independent animal preparations. The data is pooled over all MEAs per test group. Concentration-response effects are shown as mean values ± SEM. Statistical analysis includes ANOVA followed by Student’s paired t-test when compared to native activity, unpaired t-test when compound effects are compared with each other. P values ≤ 0.05 are represented with *, p ≤ 0.01 with ** and p ≤ 0.001 with ***. Heat maps show only colored rectangles if p ≤ 0.05, colors encode effect sizes as shown in the color legend. The data for the different drugs are based on the following numbers of MEA experiments: DMSO: 12. muscimol: 7, baclofen: 8, diazepam: 11, clonazepam: 14, zolpidem: 12, flunitrazepam: 12, THIP: 9, Thio-THIP: 9, DS2: 11, DS1: 10, [DS2 + 3 μM THIP]: 17, [DS2 + 15 μM THIP]: 8, [THIP + 300 nM DS2]: 12, [THIP + 1 μM DS2]: 11, [THIP + 3 μM DS2]: 15, [diazepam + 30 nM DS1]: 9, [DS1 + 50 nM diazepam]: 14.

Immunocytochemistry and microscopy

Primary prefrontal cortex neurons were fixed for 20 min with phosphate-buffered saline (PBS) containing 4% paraformaldehyd, and 4% sucrose, followed by blocking with PBS containing 40 nM NH4Cl. Membrane permeabilization was performed with PBS containing 0.1% Triton-X100 for 5 min. Permeabilized cells were blocked using PBS contining 1% BSA, 2% goat serum and 0.05% Tween20). Primary and secondary antibodies were incubated at room temparature for 1 h each in a humified chamber. The following antibodies and dilutions were used: α1 GABAAR (Synaptic Systems; 1:500), synapsin-1 (New England Biolabs; 1:200), β3-tubulin (Sigma, 1:1000), Hoechst-Bisbenzimid (Sigma Aldrich, 1 μg/ml), and secondary antibodies (1.500; Alexa fluor 488 and 594-conjugated goat-anti-mouse and goat-anti-rabbit, Invitrogen). Images were acquired using a Nikon Eclipse fluorescence microscope. Image analysis (synapse isolation) was performed using ImageJ software (NIH). Images were analyzed by semi-automatic image quantification tools (MS Excel macro-based in-house analyses; ImageJ, Rawak Software, NIH, USA). The following parameters were quantified per image, means and SEM’s were calculated afterwards: cell number: absolute number of nuclei / field (marker: nuclear staining, automatic counting after image processing (binary, watershed), neuronal number: absolute number of neuronal soma / field (marker: HuC/D-positive objects, manual and semi-automatic counting), synapse number: absolute number of synapse punctae / field (image binarized, automatic analysis: local automatic threshold setting, watershed filter for object separation).

Western blotting

The primary cortical cells and mouse brains were lysed using RIPA lysis buffer. SDS gel electrophoresis was performed using 12% pre-cast Bis-Tris gels (Novex™, NuPAGE™). Immunoblotting was performed using iBlot System and transfer Stacks PVDF. All steps were performed according to the manufaturer’s instructions. 10 μg protein was loaded per lane. Membranes were blocked for 1 hour using WesternBreeze Blocker solution (all materials from Invitrogen). The following primary antibodies and dilutions were used: α1 GABAAR (Synaptic System, 1:375), α3 GABAAR (Millipore, 1:200), α5 GABAAR (Abd-Serotec, 1:200), PSD-95 (Cell Signalling, 1:1000) and SNAP-25 (Synaptic Systems, 1:5000). Two α2 GABAAR antibodies were tested but were found to lack specificity. Primary antibodies were incubated over night at 4°C. Secondary antibodies (goat-anti-mouse, goat-anti-rabbit, both AP-conjugated, Life Technologies) were incubated for 1 h at room temperature. AP-conjugate was incubate for 5 min before signal acquisition using BioRad ChemiDoc XRS System and Gen5 Software (BioRad) for band quantification. Data from at least 3 lysates were summarized for band quantification. Western blot data is shown as mean values ± S.D.


Primary neurons were harvested on the same day as the MEA recordings were performed, and cDNA derived from mouse prefrontal cortex were used as control. Total RNA was extracted using RNA mini kit from Qiagen (Thermo Fisher Scientific, Waltham, MA) according to the manufacturer’s protocol. The reverse transcription was performed using qScript™ cDNA SuperMix (Quanta Biosciences, Gaithersburg, MD) on a standard PCR machine (25°C for 5 min, 42°C for 30 min, 85°C for 5 min) and cDNA stored at -20°C until further processing. qPCR was performed essentially as previously described in 96-well plates (Agilent Technologies, Santa Clara, CA) mixing PerfeCTa SYBR Green FastMix (Quanta Biosciences), nuclease free water (Qiagen, West Sussex, UK) and primers (TAG Copenhagen A/S (Copenhagen, Denmark) (Table 2) [31]. The Primer pairs were validated using a serial dilution of cDNA and only primers that showed single product amplification and efficiency of 100% (± 5%) were used for further analyses. The qPCR was performed with an initial denaturation step of 95°C for 30 s, followed by 40 cycles of 5 s at 95°C, 60°C for 15 seconds and 72°C for 10 s. To assure single-product amplification, a dissociation curve analysis was performed consisting of 60 s at 95°C, 30 s at 55°C and 30 s at 95°C. The qPCR was performed using the Agilent Mx3005P qPCR system (Agilent Technologies), and the corresponding MxPro software was used to determine the Ct values. The ΔCt values were calculated using 2(Reference Ct—Target Ct) as previously described [32].


MEA recordings and multi-parametric analysis of network activity in primary cortical neurons

In this study the effects of various pharmacological tools on network activity were characterized in MEA recordings at primary neurons from murine frontal cortex, and in our analysis of these data we took advantage of the high-content information provided by multichannel recordings. Following an outline of some basic characteristics of the primary cortical neurons used for the recordings and of the principles of the MEA recordings and the analysis of the data from them in this section, these results will be outlined in sections 3.2–3.6.

Basic characteristics of the primary cortical neurons. As mentioned in section 2.2, the primary neurons were used for the MEA recordings between 28 and 35 days in vitro. Due to the serum used in the culture medium glia survival is supported in these cultures, and mainly because of proliferation of glia during the first 4 days after plating these neuron-glia co-cultures thus consist of approximately 20% neurons and 80% astrocytes including 1% microglia [30]. This neuron/glia ratio of ~0.25 differs from the reported neuron/glia ratio of ~0.8 in mouse frontal cortex in vivo [33]. On the other hand, we have previously determined that approximately 20% of the neurons in these cultures are GABAergic neurons, which is in excellent agreement with ratio of GABAergic neurons (relative to total number of neurons) in mouse frontal cortex in vivo [30, 34]. In the present study, we investigated the composition of the cortical networks and the nature and degree of synapse formation in them by means of immunocytochemistry using antibodies targeting synapsin-1, β3-tubulin and Hoechst-Bisbenzimid as markers for synaptic punctae, neurons and nuclei, respectively (n = 6). As can be seen from Fig 1A, the structure and branching pattern of the neuronal networks looked comparable to those in vivo, and image analysis (synapse isolation) of cultures stained for synapsin-1 identified a high number of synaptic punctae per neuron. Although synapsin-1 is a neuron-specific phosphoprotein that binds selectively to vesicles in the presynaptic terminal and thus exclusively is a presynaptic marker [35], this nevertheless demonstrates the formation of a plethora of poly-synaptic connections in the cortical networks analogeously to in vivo.

Fig 1. Biochemical characterization of cortical network characteristics and GABAAR subunit expression in primary cortical neurons and in mouse frontal cortex tissue.

A. Immunocytochemistry characterization of the primary cortical neurons (28 DIV). i. Staining with antibodies for synapsin-1 (green), β3-tubulin (red) and Hoechst-Bisbenzimid (blue). ii. Neurons. iii. Isolated synaptic punctae. iv. Nuclei. B. Immunocytochemistry characterization of α1 GABAAR protein expression in the primary cortical neurons (28 DIV). Staining for α1 (red), β3-tubulin (green) and Hoechst-Bisbenzimid (blue). C. Western blot analysis of α1, α3 and α5 GABAAR protein expression levels in the primary neurons (7, 14, 21, 28 and 35 DIV). D. Western blot analysis of α1 and α3 protein expression levels in the primary neurons (7, 14, 21 and 28 DIV) and in postnatal mouse frontal cortex (7, 14, 21 and 28 days postnatally). E. RT-qPCR analysis of α4, β1, β2, β3 and δ mRNA expression levels (± S.D.) in the primary neurons and in postnatal mouse cortex tissue (relative to the expression of the reference gene RPL13a).

Next we investigated to which extent the primary cortical neurons express the different GABAAR subtypes. Immunocytochemistry analysis using anti-α1 antibody demonstrated robust expression of this subunit at synaptic densities in the neurons (Fig 1B). Moreover, the expression levels of various GABAAR subunits in the primary neurons were investigated by western blotting and RT-qPCR analysis and compared to the expression levels of the subunits in postnatal mouse frontal cortex tissue. As can be seen from Fig 1C, developmental changes in expression of the α1, α3 and α5 proteins in the primary neurons at 7, 14, 21, 28 and 35 DIV differed, with α1 subunit levels increasing during culture while both α3 and α5 expression levels decreased over time. Importantly, these opposite trends for α1 and α3 expression levels over time were found to be comparable to the trends determined for the two subunits in vivo in lysates from frontal mouse cortex 7, 14, 21 and 28 days postnatally (Fig 1D), which again were in good agreement with the developmental trends for the two subunits reported from studies in rats and primates [3639].

The expression levels of the α4 and δ GABAAR subunits in the primary neurons were also investigated by western blot analysis, and two different commercially available antibodies were tried for each subunit in these experiments. Despite these efforts we were unable to detect significant and convinving bands for either of these subunits when compared with the protein detected in control experiments performed on lysates from postnatal mouse frontal cortex. While these results certainly suggests that α4 and δ are expressed at lower levels than the α1, α3 and α5 subunits also studied in the western blotting experiments, the specificity and sensitivity of the antibodies used and/or the preparation of the lysate from the neuronal culture could also be contributing factors to the lack of detected bands for α4 and δ. Thus, the expression of α4 and δ in the primary neurons were investigated further by RT-qPCR analysis, where the respective expression levels of the mRNAs of the three β subunits also were determined. The α4 and δ transcripts were detected in similar levels in the neurons (Fig 1E). However, the expression levels of mRNAs for both subunits were substantially lower than the levels determined for the β1, β2 and β3 transcripts, with the levels of α4 and δ mRNAs being 11-, 1.7- and 11-fold and 9.3-, 1.5- and 9.2-fold lower, respectively, than those determined for β1, β2 and β3 (Fig 1E). For comparison, we also performed RT-qPCR analysis of postnatal mouse frontal cortex. It is important to stress that absolute mRNA levels of proteins in the primary neurons and in mouse frontal cortex are not directly comparable since the cellular composition of the tissue and the culture are very different, and thus the mRNA levels of α4, β13 and δ in the tissue were as expected higher than the levels for the subunits in the primary neurons (Fig 1E). Interestingly, however, the relative expression of the five subunits followed roughly same pattern as seen in postnatal mouse frontal cortex, with a somewhat higher relative expression of δ compared being the major difference (Fig 1E). In conclusion, the expression levels of α4 and δ mRNAs in the primary neurons determined in the RT-qPCR analysis are sufficiently high to suggest that the subunits could be expressed at protein level, and importantly the lower expression levels of these two subunits compared to those of other α subunits and of the β subunits are in good agreement with the relative subunit expression levels in mouse frontal cortex. On the other hand, the apparently low expression levels of δ-GABAARs in the primary neurons used for the MEA recordings naturally raises the question, to which extent pharmacological modulation of δ-GABAAR signalling is capable of influencing network activity, which will be address further in the Discussion section.

MEA recordings and multi-parametric analysis of network activity. Spike rate is a parameter describing general activity but this is not nessecarily the most descriptive parameter that can be derived from MEA recordings. Thus, multi-parametric data analysis has in recent years gained more attention as spatio-temporal recordings of action potentials from numerous individual neurons offer additional insights into network functionality [17]. In addition to information about the effects of a substance on spike rates and burst rates, information about its impact on synchronicity, regularity of oscillation, burst structure and network connectivity can also be derived by this analysis (Fig 2A). In particular burst structure characteristics are essential features for describing the changes in the activity patterns induced by a substance. Moreover, analysis of synchronicity is possible with a high resolution in time and per neuron, and oscillatory behaviour can be measured as the rates of action potentials occurring with periodicity over time (Fig 2A). Both synchronicity and oscillation are important characteristic phenomena in neuronal network activity in vitro [17, 20, 22]. We observed this synchronized and regular activitiy pattern also in vivo using multi-electrode intra-cortical recordings which underlines the physiological relevance of the in vitro patterns (in-house data).

Fig 2. Multiparametric analysis of cortical neuron network activity.

A. Recording setup and multiparametric analysis of cortical neuron network activity. i. Culture of neuronal networks on MEA neurochips. Two-well MEAs with 2x32 electrodes were used to acquire extra-cellular action potentials called spikes. ii. Examples of raw data from MEA recordings at cortical neurons. Wave forms from different neurons are separated yielding high-quality spike train data of single neurons in a network. iii. Spike raster plots of native cortical activity (control) and cortical activity after acute treatment with 300 nM diazepam or 5 μM picrotoxin. The augmentation and inhibition of GABAAR signaling mediated by the two respective drugs is observed to reduce and increase overall spiking and bursting activity, respectively. iv. Multiparametric analysis of MEA data. Top: Raw data (magnified detail from a spike raster plot, iii) with the origin of the four defined categories of activity parameters indicated. Bottom: Scheme of two simplified bursts outlining some of the major General Activity [burst inter burst interval (IBI) and burst period] and Burst Structure [burst duration, burst plateau, burst amplitude, burst inter-spike interval (ISI) and burst area] parameters extractable from the recordings. B. Stability of spike rate and burst rate of cortical networks recorded over 19 h in the absence of drug. C. Exemplification of the data presention in Figs 310. The effects of cumulatively increasing concentrations of the GABAAR PAM methaqualone on network activity parameters are given as concentration-response curve for the “Spike Rate” parameter (top) and as a heat map depicting statistically significant changes in several activity parameters relative to native activity (the activity at time point 0, 100%, Student’s paired t-test, p≤0.05) (bottom). The methaqualone data has been published previously [22].

The principles of the MEA recordings, the experimental set-up, the raw data obtained from the recordings, and the subsequent multi-parametric data analysis performed in this study are illustrated in Fig 2A. The 204 activity-describing parameters calculated based on the spike trains from the multichannel recordings are divided into four categories (Fig 2A). “General Activity” parameters are global network activity descriptors (e.g. spike rate, burst rate, % of spikes in bursts and burst period), whereas “Burst Structure” parameters describe the internal structure of spikes within a high-frequency spiking phase (e.g. spike frequency in bursts, spike rate in bursts, spike density) as well as the overall burst structure (e.g. the duration, area, plateau of the burst). “Oscillatory Behavior” parameters are the standard deviations associated with main General Activity and Burst Structure parameters, and these parameters are thus descriptors of the regularity of bursting events within experimental episodes, with higher values indicating less regular general activity or less regular burst structure. Finally, the “Synchronicity” parameters include those representing the coefficient of variation over the network. Thus, the Synchronicity CVnet values are reflecting the level of synchronization amongst the neurons, i.e. the degree of variation for the respective General Activity or Burst Structure parameter between individual units in a network. The lower the CVnet, the higher the synchronicity among neurons and vice versa. The 40 activity parameters shown in heat maps in Figs 310 represent a wide view on concentration-dependent effects of agents and thus the phenotypic fingerprint which is unique to every compound but similar between compounds with same modes of action. Full names and definitions of the 40 parameters are given in S1 Table.

Fig 3. Changes in cortical network activity induced by 7–10 cumulatively increasing concentrations of the GABAAR agonist muscimol and the GABABR agonist baclofen.

The heat maps present statistically significant changes in 40 activity parameters relative to native activity (no drug, 100%) (Student’s paired t-test, p≤0.05). The concentration-response relationships for the drugs at 10 selected activity parameters are given as mean ± S.E.M. relative to native activity (no drug, 100%).

Fig 4. Changes in cortical network activity induced by 8–9 cumulatively increasing concentrations of the αβγ GABAAR PAMs diazepam, flunitrazepam, clonazepam and zolpidem.

The heat maps present statistically significant changes in 40 activity parameters relative to native activity (no drug, 100%) (Student’s paired t-test, p≤0.05). The concentration-response relationships for the drugs at 10 selected activity parameters are given as mean ± S.E.M. relative to native activity (no drug, 100%).

Fig 5. Changes in cortical network activity induced by 7–9 cumulatively increasing concentrations of the functionally selective δ-GABAAR agonists THIP and Thio-THIP.

The heat maps present statistically significant changes in 40 activity parameters relative to native activity (no drug, 100%) (Student’s paired t-test, p≤0.05). The concentration-response relationships for the drugs at 10 selected activity parameters are given as mean ± S.E.M. relative to native activity (no drug, 100%).

Fig 6. Changes in cortical network activity induced by 8–9 cumulatively increasing concentrations of the δ-GABAAR-selective modulators DS1 and DS2.

The heat maps present statistically significant changes in 40 activity parameters relative to native activity (no drug, 100%) (Student’s paired t-test, p≤0.05). The concentration-response relationships for the drugs at 10 selected activity parameters are given as mean ± S.E.M. relative to native activity (no drug, 100%).

Fig 7. Changes in cortical network activity induced by 8 cumulatively increasing concentrations of DS2 in the absence and in the presence of 3 μM or 15 μM THIP.

The heat maps to the left of the vertical hatched line present statistically significant changes in 40 activity parameters relative to native activity (no drug, 100%) (Student’s paired t-test, p≤0.05). The concentration-response relationships for the drug combinations at 10 selected activity parameters are given as mean ± S.E.M. relative to native activity (no drug, 100%). The heat maps to the right of the vertical hatched line present statistically significant changes in the 40 activity parameters between the activity induced by a specific DS2 concentration co-applied with 3 μM or 15 μM THIP relative to the activity induced by THIP on its own (3 μM or 15 μM, respectively) (100%) (Student’s paired t-test, p≤0.05).

Fig 8. Changes in cortical network activity induced by 7–8 cumulatively increasing concentrations of THIP in the absence and in the presence of 300 nM, 1 μM or 3 μM DS2.

The heat maps to the left of the vertical hatched line present statistically significant changes in 40 activity parameters relative to native activity (no drug, 100%) (Student’s paired t-test, p≤0.05). The concentration-response relationships for the drug combinations at 10 selected activity parameters are given as mean ± S.E.M. relative to native activity (no drug, 100%). The heat maps to the right of the vertical hatched line present statistically significant changes in the 40 activity parameters between the activity induced by a specific THIP concentration co-applied with 300 nM, 1 μM or 3 μM DS2 relative to the activity induced by that specific THIP concentration on its own (100%) (Student’s paired t-test, p≤0.05).

Fig 9. Changes in cortical network activity induced by 8–9 cumulatively increasing concentrations of diazepam in the absence and in the presence of 30 nM DS1.

The heat maps to the left of the vertical hatched line present statistically significant changes in 40 activity parameters relative to native activity (no drug, 100%) (Student’s paired t-test, p≤0.05). The concentration-response relationships for the drug combinations at 10 selected activity parameters are given as mean ± S.E.M. relative to native activity (no drug, 100%). The heat maps to the right of the vertical hatched line present statistically significant changes in the 40 activity parameters between the activity induced by a specific diazepam concentration co-applied with 30 nM DS1 relative to the activity induced by 30 nM DS1 on its own (100%) or relative to the activity induced by that specific diazepam concentration on its own (100%) (Student’s paired t-test, p≤0.05).

Fig 10. Changes in cortical network activity induced by 8–9 cumulatively increasing concentrations of DS1 in the absence and in the presence of 50 nM diazepam.

The heat maps to the left of the vertical hatched line present statistically significant changes in 40 activity parameters relative to native activity (no drug, 100%) (Student’s paired t-test, p≤0.05). The concentration-response relationships for the drug combinations at 10 selected activity parameters are given as mean ± S.E.M. relative to native activity (no drug, 100%). The heat maps to the right of the vertical hatched line present statistically significant changes in the 60 activity parameters between the activity induced by a specific DS1 concentration co-applied with 50 nM diazepam relative to the activity induced by 50 nM diazepam on its own (100%) or relative to the activity induced by that specific DS1 concentration on its own (100%) (Student’s paired t-test, p≤0.05).

Under optimal culture conditions the MEA cultures display stable activity levels for several hours with only a few parameters exhibiting changed properties over time (Fig 2B). Moreover, DMSO mediates either no significant effects or negligible effects on all activity parameters when applied at assay concentrations up to 0.1%. This stability allows measurements of the effects induced by cumulatively increasing concentrations of a drug on the same network in recordings over a time period of 8–9 h and the subsequent normalization the all activity parameter data for a specific drug concentration to the intrinsic native activity recorded (control). In conclusion, robust data describes the complete concentration-response relationships for all activity parameters for the drugs.

Because of the holistic nature of the information extractable from MEA recordings on neuronal networks, there are aspects of GABAAR signaling and its contributions to overall GABAergic transmission that may be addressed in slice and patch-clamp recordings at neurons but not in these recordings. In the present study, application of cumulatively increasing concentrations of the different GABAergic agonists and PAMs did not lead to visible desensitization of the induced changes in the activity parameters over time. That is not to say that exposure of the networks to these drugs (especially at high concentrations) does not induce desensitization of individual GABAARs in the neurons. However, this ongoing desensitization (and subsequent resensitization) of individual receptors in the neurons either does not manifest itself significantly in the measured read-outs in the recordings or this desensitization may actually be imbedded in the observed changes in the various activity parameters induced by the drugs. Furthermore, it is also not possible to differentiate between the respective contributions of presynaptic and postsynaptic GABAARs to the total effects at network activity induced by a specific drug in the MEA recordings. On the other hand, provided that activity patterns in the pre-frontal cortex cultures used for the MEA recordings to a reasonable degree are reflective of cortical activity patterns in vivo, we propose that the drug-induced network activity changes in this system can offer interesting information about other aspects of GABAAR-mediated functions in an in vivo setting.

Muscimol and baclofen

Initially the effects on cortical network activity produced by selective activation of GABAARs or GABABRs were studied by applications of muscimol and baclofen, respectively. Muscimol is a pan-GABAAR agonist displaying full agonism and EC50 values in the high nanomolar/low micromolar range at various receptor subtypes expressed in oocytes or mammalian cells [4042], and baclofen is a selective full GABABR agonist exhibiting low micromolar EC50 values at the recombinant GABABRs [4345]. In the MEA recordings, muscimol and baclofen were applied at the networks at concentrations up to 3 μM and 10 μM, respectively, and activity changes induced by the two drugs must thus be assumed to arise from substantial (if not maximal) degrees of activation of GABAARs and GABABRs, respectively. Importantly, the concentration-response relationships exhibited by muscimol (EC50 ~100 nM) and baclofen (EC50 ~1 μM) at major General Activity parameters such as “Spike Rate” and “Burst Rate” were in concordance with the reported potencies for the two agonists at their respective recombinant receptors. Muscimol and baclofen mediated very similar changes in the General Activity parameters, with both drugs inducing overall suppression of network activity in the form of decreased spike and burst rates and increased burst periods and inter-burst intervals (Fig 3). In contrast, the two drugs modulated several Burst Structure parameters differently, with muscimol decreasing burst durations and amplitudes and baclofen inducing the opposite effects (Fig 3). Moreover, whereas GABAAR activation mainly decreased the variation of General Activity and Burst Structure parameters between different bursts, GABABR activation had more subtle impact on this variation and in some cases even increased it (Oscillatory Behavior parameters, Fig 3). Thus, the changes in neuronal network activity resulting from stimulation of GABAAR and GABABR signalling were phenotypically distinct. In the subsequent experiments we probed the contributions of different receptor populations to the GABAAR-mediated effects.

Positive allosteric modulators (PAMs) of αβγ GABAARs

To assess the network effects arising from selective augmentation of synaptic αβγ GABAAR signalling, the benzodiazepines diazepam, flunitrazepam and clonazepam and the benzodiazepine-site PAM zolpidem were characterized at the neuron cultures. All these four PAMs act through the high-affinity benzodiazepine binding sites formed at the extracellular α(+)(–) subunit interface in α1,2,3,5βγ GABAARs, and in the concentration ranges used in the MEA recordings the modulators will act exclusively at these receptors without affecting other subtypes. Diazepam, flunitrazepam and clonazepam are fairly non-selective PAMs, and the network effects mediated by these modulators must thus be assumed to arise from modulation of all α1,2,3,5βγ receptors [4649]. In contrast, zolpidem is α1-preferring PAM exhibiting EC50 values of ~100 nM at α1βγ receptors, ~10-fold higher EC50 values at α2βγ and α3βγ receptors and negligible activity at α5βγ receptors in heterologous expression systems [48, 5052]. Thus, the network effects mediated by low concentrations of zolpidem must predominantly be ascribed to α1βγ receptors, whereas α2βγ and α3βγ subtypes are likely to contribute the effects observed at higher concentrations of the modulator.

All in all, diazepam, flunitrazepam, clonazepam and zolpidem induced similar effects at the neuronal networks in the MEA recordings (Fig 4). However, the degrees of modulation exerted by the four PAMs differed somewhat at some of the activity parameters, most notably flunitrazepam exerted significant effects at more Burst Structure parameters than the other PAMs. The changes in the various activity parameters brought on by the four PAMs were, with a few exceptions, in the same qualitative directions as those induced by muscimol. Interestingly, however, sub-saturating concentrations of muscimol induced considerably more pronounced effects on major General Activity parameters such as “Spike Rate” and “Burst Rate” than saturating concentrations of the PAMs (Figs 3 and 4). This difference could be rooted in this pan-GABAAR agonist targeting a broader spectrum of GABAAR subtypes than the benzodiazepine-site PAMs. Alternatively, since the PAMs are dependent on concomitant agonist binding to the receptors to mediate their effects, the maximal degrees of modulation induced by them in these recordings could also be limited by the endogenous concentration of GABA in the assay.

In concordance with their somewhat higher potencies as PAMs at recombinant α1,2,3,5βγ receptors, flunitrazepam and clonazepam were observed to be slightly more potent than diazepam at most General Activity and Burst Structure parameters. Interestingly, the degrees of modulation induced by 100 nM zolpidem and 100 nM diazepam at the various activity parameters were largely comparable (Fig 4). Since diazepam and zolpidem are essentially equipotent PAMs at α1βγ receptors expressed in Xenopus oocytes (EC50 values ~100 nM) [47, 48, 50, 51], the two modulators must be assumed to exert comparable degrees of α1βγ receptor modulation at this concentration, whereas diazepam (100 nM) in contrast to zolpidem (100 nM) also will mediate substantial modulation of α2,3,5βγ receptors. Thus, the comparable effects of the two modulators is likely to be a reflection of the fact that α1βγ receptors (including α1αxβγ receptors comprising an α1(+)(–) subunit interface) are the major synaptic GABAAR subtypes in cortical neurons [2].

THIP and Thio-THIP

The orthosteric GABAAR ligands THIP and Thio-THIP both exhibit functional selectivity for δ-GABAARs over other receptor subtypes. While THIP is an agonist at a wide range of GABAARs, it exhibits substantially higher maximal responses (relative to GABA) at δ-GABAARs than at αβγ receptors [42, 5355]. More importantly, THIP is also a more potent agonist at α4βδ receptors than at αβγ and αβ receptors, and this selectivity for δ-GABAARs within a certain concentration range has made THIP the prototypic pharmacological tool for these receptors [42, 5356]. The close structurally related analog Thio-THIP is a functionally subtype-selective α4βδ GABAAR ligand, as it acts as a partial agonist at α4β1δ and α4β3δ receptors and exhibits negligible agonist activity at α4β2δ and αβγ GABAARs [57].

Both THIP and Thio-THIP induced significant changes in cortical network activity in a concentration-dependent manner (Fig 5). THIP exhibited EC50 values in the 10–30 μM range at the majority of the General Activity parameters, and applications of 3 μM or 10 μM THIP produced significant effects at most of the activity parameters (Fig 5). In electrophysiological recordings at recombinant GABAARs expressed in Xenopus oocytes or mammalian cells, THIP has been found to induce α4βδ receptor signaling without concomittant activation of αβγ receptors within a concentration range spanning from high-nanomolar concentrations to approximately 10 μM [42, 54, 55, 57], which indicate that the significant network effects induced by THIP at 3 and 10 μM concentrations could be mediated predominantly through δ-GABAARs. Conversely, in slice recordings high-nanomolar concentrations of THIP have been shown to induce robust tonic currents in neurons expressing α4βδ GABAARs as major extrasynaptic receptors [5760], suggesting that significant network effects perhaps could have been expected to arise from lower THIP concentrations than 3/10 μM. Thus, if one were to go by the ability of THIP to induce tonic currents at high-nanomolar concentrations the fact that concentrations of 3 μM and higher were required to induce signficant network effects could be interpreted either as lack of expression of δ-GABAARs in the neurons or as a reflection of negligible contributions of δ-GABAAR signaling to network activity. On the other hand, even though the low degree of δ-GABAAR occupancy and activation seen at high-nanomolar concentrations of THIP is able to tonic currents there does not necessarily have to be a 1:1 correlation between its effects at these concentrations and the THIP concentrations capable of giving rise to significant changes in the activity parameters in the MEA recordings. In conclusion, although the observation that THIP first induces significant networks effects at 3/10 μM concentrations where the agonist is known to begin to activate αβγ and other GABAARs as well could be taken as an indication that its network effects could arise from these receptors rather than from δ-GABAARs, it could also mean that the δ-GABAAR-mediated effects on network activity requires a higher degree of receptor occupancy by THIP. In the latter case, the networks effects induced by THIP (3/10 μM) could be mediated through both αβγ and δ-GABAARs.

Whereas THIP could be tested at the networks at concentrations up to 3 mM, application of Thio-THIP at concentrations of 300 μM and higher resulted in neurotoxic effects. Thus, Thio-THIP was only tested at concentrations up to 100 μM, where these effects were not observed. Within this concentration-range Thio-THIP mediated changes in substantially fewer network activity parameters than THIP, and significant effects were mostly seen at concentrations of 30 μM and 100 μM (Fig 5). In view of its negligible activity at recombinant αβγ GABAARs at concentrations up to 100 μM, the effects of Thio-THIP on network activity most likely arise from its agonism at δ-GABAARs, and the fact that significant effects typically only arises from compound concentrations of 30 μM or 100 μM seems to concord with its potency as a α4βδ receptor agonist. Moreover, judging from its functional selectivity profile at the three recombinant α4βδ subtypes these effects are likely to be mediated through α4β1δ and/or α4β3δ receptors [57].

DS1 and DS2

Next the close structurally related allosteric ligands DS1 and DS2 were tested at the cortical networks. DS1 and DS2 have been reported to be selective modulators of δ-GABAAR (in particular α4βδ and α6βδ) over α1,2,3,5β2γ2 and α4β3 receptors expressed in oocytes and mammalian cells [61, 62]. DS1 exhibits pronounced intrinsic activity and thus acts both as an allosteric agonist and a PAM (ago-PAM) at recombinant α4β3δ receptors, whereas DS2 has been reported to be a pure PAM at these receptors [61, 62]. Importantly, however, both compounds modulate αβγ receptors in the same concentration range as δ-GABAARs, and the proposed δ-GABAAR selectivity of these compounds are thus rooted in the dramatically higher efficacies exhibited by them as modulators of these receptors than at the αβγ receptors [54].

In the MEA recordings DS1 and DS2 were both applied in concentration ranges that cover most of their effective concentration-response relationships at recombinant α4β3δ GABAARs [54, 61, 62]. Interestingly, DS2 either mediated very subtle effects or no significant effects at the various activity parameters at concentrations up to 5 μM (the highest concentration tested due to restrictions in terms of the maximum assay concentration of DMSO), whereas DS1 induced pronounced effects in a concentration-dependent manner at the majority of parameters in all four classifications (Fig 6). Importantly, significant effects were observed from applications of even low nanomolar DS1 concentrations, and the ago-PAM exhibited EC50 values in the 100–300 nM range at several of the major General Activity and Burst Structure parameters, which is in agreement with its reported potency at recombinant α4βδ receptors [54, 61]. The DS1-induced changes in the activity parameters were all in the same directions as those mediated by THIP (3/10 μM) and by Thio-THIP (Fig 5), and the changes were also phenotypically similar to those produced by the benzodiazepine-site PAMs (Fig 4). Assuming that the network effects mediated by THIP (3/10 μM) and Thio-THIP predominantly can be ascribed to δ-GABAAR activation, the substantially more pronounced changes in the activity parameters mediated by DS1 could be ascribed to the higher efficacy of this ago-PAM at δ-GABAARs than THIP (3/10 μM) and the partial agonist Thio-THIP [42, 54, 55, 57, 61].

We found the dramatically different efficacies of DS1 and DS2 in the MEA recordings interesting. The DS2 sample used in the MEA recordings was found to exhibit robust PAM activity at recombinant α4β3δ GABAARs expressed in Xenopus oocytes, and thus the negligible effects of the PAM at cortical network activity could not be ascribed to lack of δ-GABAAR activity in this specific sample. Moreover, as outlined above the effects mediated by DS1, Thio-THIP and, to some extent, THIP suggest that augmentation of δ-GABAAR signaling is impact network activity. Thus, we speculated that the negligible effects mediated by DS2 could be rooted in GABA concentrations surrounding extrasynaptic δ-GABAARs in the neurons being too low to enable the PAM to mediate its effects. To investigate this possibility, we studied the network effects induced by DS2 in the presence of a trace concentration of THIP. Co-application of DS2 (0.1 nM-5 μM) with 3 μM THIP produced very subtle changes in the activity parameters, both when compared to the activity recorded in native cells and to the activity arising from the initial application of 3 μM THIP (Fig 7). Even when DS2 (0.1 nM-5 μM) was co-applied with 15 μM THIP, a concentration of the agonist that on its own induced significant changes in several activity parameters and thus must be assumed to exert robust δ-GABAAR activation, the effects induced by the PAM were subtle albeit more substantial than those induced in the presence of 3 μM THIP (Fig 7). Interestingly, DS2 predominantly augmented the 15 μM THIP-mediated effects at Burst Structure parameters, whereas the General Activity parameters were largely unaffected by the presence of the modulator (Fig 7).

In reverse experiments, the concentration-response relationships for THIP at the network activity parameters were determined in the presence of 300 nM, 1 μM or 3 μM DS2, three concentrations that cover most of the effective concentration range of DS2 (~EC30-EC90) at recombinant α4β3δ GABAARs [54, 61, 62]. The presence of DS2 during these recordings only impacted the concentration-response relationships exhibited by THIP slightly, the most substantial modulation being observed at lowest PAM concentration (Fig 8). The presence of 300 nM DS2 in the assay right-shifted the concentration-response relationships displayed by THIP or reduced its efficacy at several General Activity and Burst Structure parameters (Fig 8). Albeit this modulation was subtle this DS2 concentration thus seemed to counteract the network effects arising from THIP-mediated δ-GABAAR modulation, whereas the presence of higher concentrations of the modulator (1 μM and 3 μM) generally were without effect (Fig 8).

Diazepam and DS1 combinations

Having studied the changes in network activity mediated by selective modulators of αβγ GABAARs and δ-GABAARs, we next set out to investigate the putative functional interplay between the two receptor classes in the neurons, i.e. to which extent concomittant δ-GABAAR signalling would impact the network changes mediated by αβγ GABAARs and vice versa. DS1 and diazepam were applied as selective mediators of signalling through these two receptor classes in the recordings, where the concentration-response relationships for one modulator were determined at the networks in the concomitant presence of a fixed low concentration of the other. Concentrations of 30 nM DS1 and 50 nM diazepam were used for the recordings, since these concentrations of the respective drugs produced small but significant changes in the majority of activity parameters in the original recordings (Figs 4 and 6).

The network activity changes induced by diazepam (1 nM-10 μM) in the presence of 30 nM DS1 were all characterized by the same directions as those induced by the benzodiazepine on its own (Fig 9). In these recordings, application of 30 nM DS1 on its own induced more modest effects on the activity parameters than expected based on its concentration-response relationships in the original DS1 recordings (Fig 6). Nevertheless, when co-applied with this trace concentration of DS1 diazepam was strikingly less efficacious at the networks than when applied on its own. In fact, the concentration-response relationships exhibited by the “diazepam (30 nM DS1)” combination at numerous activity parameters (including major General Activity and Burst Structure parameters such as “Spike rate”, “Burst rate”, “Burst duration” and “Burst amplitude”) were dramatically right-shifted compared to those evoked by diazepam on its own, in some cases up to ~30-fold (Fig 9). Thus, the concomittant presence of this low DS1 concentration appeared to decrease the sensitivity of the neurons to the diazepam-mediated αβγ GABAAR signalling.

In another experiment the roles of the two modulators were reversed, and DS1 (0.1 nM-3 μM) was co-applied with 50 nM diazepam at the networks (Fig 10). In agreement with the original diazepam recordings (Fig 4), application of 50 nM diazepam mediated significant effects on the majority of activity parameters, inducing responses constituting up to ~30% of the responses induced by saturating diazepam concentrations (Fig 10). The network activity changes arising from DS1 in the presence of 50 nM diazepam were all characterized by the same qualitatively directions as those induced by DS1 on its own. Moreover, when the isolated effects mediated by 50 nM diazepam on the networks were taken into account, the concentration-response relationships exhibited by the “DS1 (50 nM diazepam)” combination at the activity parameters either did not differ signifiantly or were only slightly different (mostly right-shifted) compared to those displayed by DS1 on its own (Fig 10). Thus, in contrast to the observation made in the reverse experiment, a moderate level of stimulation of αβγ GABAARs thus did not seem to affect the network effects mediated by DS1 in this experimental set-up substantially.


In the present study the effects of various pharmacological tools characterized by different modulatory properties and selectivity profiles at GABAARs on cortical neuronal network activity were characterized investigated by use of MEA recordings and multiparametric data analysis. We report that selective augmentation of GABAAR and GABABR signaling by the pan-agonists muscimol and baclofen, respective, mediate phenotypically distinct changes in network activity, and that the networks effects induced by wide range of GABAAR modulators with different subtype-selectivity profiles largely were in the same qualitative directions, albeit with some interesting exceptions. Thus, benzodiazepine-site PAMs selective for αβγ GABAARs as well as the reported δ-GABAAR-selective agents DS1 and Thio-THIP induced robust changes in a broad range of activity parameters. Interestingly, the efficacious modulation of network activity mediated by the ago-PAM DS1 was contrasted by the negligible effects exhibited by its close structural analog DS2, another reported δ-GABAAR-selective PAM, at the neurons. Finally, in studies of the putative functional interplay between αβγ GABAARs and δ-GABAAR, co-administration of diazepam with a low but effective concentration of DS1 was found to decrease the apparent potency of the bezodiazepine at numerous activity parameters, whereas low levels of concomittant αβγ GABAAR stimulation had little impact on the DS1-induced network effects.

Interpretations made in any study probing native GABAAR signaling with pharmacological tools are obviously reliant on the reported functional properties of these at recombinant receptors being accurate and as detailed as possible. Furthermore, although functionalities of ligands determined at recombinant GABAARs usually are assumed to be mirrored at the native receptors, this may not always be the case. This is particular true for the α4βδ GABAARs that assemble into different functional receptor stoichiometries and arrangements in heterologous expression systems that may not all exist in vivo [6367]. Thus, even though the αβγ GABAAR selectivity of the benzodiazepine-site PAMs [4652], the efficacy-based functional selectivity of DS1 and DS2 as δ-GABAAR modulators [54, 61, 62], and the functional δ-GABAAR selectivity of THIP and Thio-THIP [42, 56, 57] are well-founded in the literature, such considerations are also valid for this study. It is also important to stress that while α1,2,3βγ GABAARs and δ-GABAARs (mainly α4βδ) are the predominant synaptic and extrasynaptic receptors in cortical neurons, other subtypes are likely to be expressed at both sites in these neurons and to contribute to phasic and tonic inhibition as well, analogously to what has been demonstrated in other brain regions [11, 13, 6870]. The reported expression of extrasynaptic α5βγ receptors in layer 5 cortical neurons [71] is particular relevant, since the networks effects induced by diazepam, flunitrazepam and clonazepam thus potentially could comprise a component arising from activation of these receptors. As outlined in Results, however, the similarity of the networks effects mediated by the benzodiazepines to those of zolpidem, a PAM with negligible α5βγ activity, strongly suggests that the effects predominantly are attributable to activation of α1,2,3βγ receptors (Fig 4). Thus, while keeping the heterogeneity of native GABAARs and the other aspects outlined above in mind, we propose that the GABAAR ligands applied in this study relatively specifically delineate the networks effects arising from augmentation of the signalling of αβγ GABAARs and δ-GABAARs.

Another general concern in studies of GABAAR-mediated effects in neuronal cultures is obviously to which extent the relative distribution and the expression levels of various receptor subtypes in the cultures mirror those in native tissues and to which degree effects observed for various pharmacology tools here can be extrapolated to the in vivo situtation. As evidenced by the substantial expression levels detected for the α1, α3 and β13 subunits in neuronal culture lysates and by the robust network activity changes mediated by four benzodiazepine-site PAMs in concentration ranges in good agreement with their modulatory potencies at recombinant αβγ GABAARs (Figs 1 and 4), there is little doubt that αβγ GABAARs are expressed in the primary neurons and are of major importance for the level of spontaneous activity in these networks. However, when it comes the δ-GABAARs, the data presented in this study is admittedly more ambiguous and open to interpretation. Even through the significantly lower expression levels of α4 and δ subunits compared to β13 in the primary neurons are in concordance with the relative expression of these subunits in postnatal mouse frontal cortex (Fig 1E), it is reasonable to question whether δ-GABAARs expressed at such low levels would be able to exert substantial effects on network activity. Unfortunately, the network effects mediated by the four drugs applied in this study to elucidate the importance of these δ-GABAARs are also quite ambiguous. The fact that DS1 and Thio-THIP mediate robust modulation of the majority of activity parameters and at these exhibit concentration-response relationships that concord with their respective potencies at recombinant δ-GABAARs seem to support the notion of these receptors being important for spontaneous activity in the networks (Figs 5 and 6). As outlined in detail in the Results section, the concentration-response relationship exhibited by THIP in its modulation of network activity can both be argued to substantiate and to disprove an involvement of δ-GABAARs, and as such the data for this drug does not offer clarity on the issue. Finally, the negligible modulation of network activity mediated by the δ-selective PAM DS2, both when applied on its own and with THIP, conversely suggests that the contributions of δ-GABAARs to network activity changes could be minute (Figs 68). However, in contrast to its potent and highly efficacious modulation of recombinant α4βδ GABAARs, DS2 is not a particular potent inducer of tonic inhibition through native α4βδ receptors in murine thalamic ventrobasal neurons, where it only elicits significant tonic currents at a concentration of 3 μM [61, 62]. Thus, the fact that DS2 in this study only was tested at concentrations up to 5 μM could perhaps explain its modest effects on network activity. In conclusion, we favor an interpretation of these data where the observed effects of DS1, Thio-THIP and, to some extent, THIP (3/10 μM) on network activity are mediated predominantly through δ-GABAARs. Although we can not completely exclude the possibility that the low expression levels of δ-GABAARs in the neurons could mean that these receptors do not contribute significantly to the observed network activity changes, any alternative explanation would require both DS1 and Thio-THIP to mediate their robust network effects through other targets than δ-GABAARs, which we find a more unlikely scenario.

The dramatically different modulation of network activity mediated by the close structural analogs DS1 and DS2 in the MEA recordings is truly striking. As mention above, we propose that the DS1-mediated effects are arising from δ-GABAAR modulation, and the effective concentration ranges exhibited by DS1 at the various activity parameters are certainly in good agreement with the reported potencies for it as an ago-PAM at recombinant α4βδ GABAARs (Fig 6) [54, 61]. To our knowledge, there are no published studies of the modulation exerted by DS1 at native δ-GABAARs, and thus it remains to be seen whether DS1 analogously to DS2 displays different modulatory potency in its induction of tonic currents in slice recordings than at recombinant δ-GABAARs. However, considering that DS1 is a ~10-fold more potent PAM at recombinant α4βδ GABAARs than DS2 and, in contrast to DS2, also exhibits pronounced intrinsic agonist activity at the receptors [54, 61], DS1 would be expected to be a more potent and efficacious potentiator of native extrasynaptic δ-GABAARs than DS2. That being said, the dramatically different effects induced by DS1 and DS2 on cortical network activity can not be rationalized solely be these differences in the modulatory properties of the compounds at the recombinant receptors, and thus it could be interesting to further address the mechanism(s) underlying DS1-mediated modulation of neuoronal network activity in future studies.

The putative functional interplay between αβγ GABAARs and δ-GABAARs in the cortical networks was probed in this study using diazepam and DS1 as pharmacological tools for the respective receptor classes. Considering the above-mentioned inconclusiveness of δ-GABAAR expression and/or the importance of these receptors for the network activity in these cultures, any interpretations of observations made in these experiments inevitably will depend heavily on whether the network activity changes induced by DS1 are indeed mediated though δ-GABAARs or whether they arise from other yet unidentified activities of the drug. In the following, the DS1-mediated effects will be assumed to arise predominantly from δ-GABAAR modulation, analogously to the selective potentiation of αβγ GABAAR signaling exerted by diazepam.

Whereas a low degree of δ-GABAAR activation by DS1 was observed to reduce the sensitivity of the cortical networks to αβγ GABAAR signalling substantially, moderate activation of αβγ GABAARs did not seem to impact δ-GABAAR-mediated activity changes substantially (Figs 9 and 10). The mechanisms underlying the phenomenon of homeostatic plasticity of inhibitory neuron excitability and output are poorly understood, including how and to which extent synaptic and extrasynaptic GABAARs interact with each other to balance tonic and phasic inhibition [14]. In previous studies overexpression of α6βδ or α5βγ2 receptors at extrasynaptic sites in hippocampal neurons have not only been shown to result in increased tonic currents but also in significantly decreased synaptic GABAAR responses [72, 73]. In one of these studies, the reduction in synaptic transmission was ascribed to competition between extrasynaptic and synaptic receptors for a limited number of receptor slots at the neuron surface [73]. While this may be a plausible explanation for the observed effects in neurons with manipulated receptor expression levels, it can not be extended to this study where the putative functional interplay between the two receptor groups were assessed by pharmacological tools at neurons characterized by endogenous receptor expression levels. In this set-up, the observed differences between the concentration-response relationships for one modulator in the absence and in the presence of another modulator reflect the acute effects arising from low levels of concomitant signalling of the other receptor group. Thus, although dynamic regulation of cell surface expression levels of receptors in these neurons very well could be an underlying cause of the observed effects, other mechanisms could be involved as well, just as the homeostatic plasticity of inhibitory synapses could be rooted in multiple molecular and cellular mechanisms. For example, the phosphorylation and dephosphorylation of Ser, Thr and Tyr residues in intracellular GABAAR subunit regions mediated by various kinases and phosphatases has been proposed to constitute a dynamic balance modulating cell surface trafficking of GABAARs as well the functional properties of the receptors [14, 74]. Not having investigated these putative mechanisms in this study, we will refrain from further speculations about them.


This work should be considered complementary to the numerous studies of synaptic αβγ GABAARs and extrasynaptic δ-GABAARs in neuronal cultures or brain slices by means of conventional electrophysiology. The network effects arising from signalling mediated by the two receptor groups were probed with several selective pharmacological tools, and the concentration-response relationships exhibited by the modulators were generally in good agreement with their functional properties at their respective recombinant target receptors. Hence, we propose that the multi-parametric analysis of MEA data allows for a detailed description of network activity changes in the cortical networks exhibited by phenotypic fingerprints determined for various GABAAR modulators and that this holistic approach to the study of these receptors offer interesting insights into the respective roles of αβγ GABAARs and δ-GABAARs and the putative functional interplay between them in the neurons.

Supporting information

S1 Table. The full names and the definitions of the 40 selected network activity parameters shown in Figs 210.



This study was supported financially by the Novo Nordisk Foundation.


  1. 1. Pinard A, Seddik R, Bettler B. GABAB receptors: physiological functions and mechanisms of diversity. Adv Pharmacol. 2010;58:231–55. Epub 2010/07/27. doi: S1054-3589(10)58010-4 [pii] pmid:20655485.
  2. 2. Olsen RW, Sieghart W. International Union of Pharmacology. LXX. Subtypes of γ-aminobutyric acidA receptors: classification on the basis of subunit composition, pharmacology, and function. Update. Pharmacol Rev. 2008;60:243–60. Epub 2008/09/16. doi: pr.108.00505 [pii] pmid:18790874; PubMed Central PMCID: PMC2847512.
  3. 3. Whiting PJ. The GABAA receptor gene family: new opportunities for drug development. Curr Opin Drug Discov Devel. 2003;6:648–57. pmid:14579514.
  4. 4. Ebert B, Wafford KA. Benzodizepine receptor agonists and insomnia: Is subtype selectivity lost in translation? Drug Discovery Today. 2006;3:547–54.
  5. 5. Enna SJ, McCarson KE. The role of GABA in the mediation and perception of pain. Adv Pharmacol. 2006;54:1–27. Epub 2006/12/21. pmid:17175808.
  6. 6. Korpi ER, Sinkkonen ST. GABAA receptor subtypes as targets for neuropsychiatric drug development. Pharmacol Ther. 2006;109:12–32. pmid:15996746.
  7. 7. Rudolph U, Möhler H. GABAA receptor subtypes: Therapeutic potential in Down syndrome, affective disorders, schizophrenia, and autism. Annu Rev Pharmacol Toxicol. 2014;54:483–507. pmid:24160694; PubMed Central PMCID: PMC3997216.
  8. 8. Möhler H. The GABA system in anxiety and depression and its therapeutic potential. Neuropharmacology. 2012;62(1):42–53. Epub 2011/09/06. S0028-3908(11)00373-X [pii] pmid:21889518.
  9. 9. Braat S, Kooy RF. The GABAA Receptor as a Therapeutic Target for Neurodevelopmental Disorders. Neuron. 2015;86(5):1119–30. pmid:26050032.
  10. 10. Farrant M, Nusser Z. Variations on an inhibitory theme: phasic and tonic activation of GABAA receptors. Nat Rev Neurosci. 2005;6:215–29. Epub 2005/03/02. nrn1625 [pii] pmid:15738957.
  11. 11. Brickley SG, Mody I. Extrasynaptic GABAA receptors: their function in the CNS and implications for disease. Neuron. 2012;73:23–34. Epub 2012/01/17. S0896-6273(11)01093-2 [pii]. pmid:22243744; PubMed Central PMCID: PMC3399243.
  12. 12. Brickley SG, Revilla V, Cull-Candy SG, Wisden W, Farrant M. Adaptive regulation of neuronal excitability by a voltage-independent potassium conductance. Nature. 2001;409(6816):88–92. pmid:11343119.
  13. 13. Glykys J, Peng Z, Chandra D, Homanics GE, Houser CR, Mody I. A new naturally occurring GABAA receptor subunit partnership with high sensitivity to ethanol. Nat Neurosci. 2007;10:40–8. Epub 2006/12/13. nn1813 [pii] pmid:17159992.
  14. 14. Mody I. Aspects of the homeostaic plasticity of GABAA receptor-mediated inhibition. The Journal of physiology. 2005;562(Pt 1):37–46. pmid:15528237; PubMed Central PMCID: PMCPMC1665492.
  15. 15. McConnell ER, McClain MA, Ross J, Lefew WR, Shafer TJ. Evaluation of multi-well microelectrode arrays for neurotoxicity screening using a chemical training set. Neurotoxicology. 2012;33(5):1048–57. pmid:22652317; PubMed Central PMCID: PMCPMC3721981.
  16. 16. Novellino A, Scelfo B, Palosaari T, Price A, Sobanski T, Shafer TJ, et al. Development of micro-electrode array based tests for neurotoxicity: assessment of interlaboratory reproducibility with neuroactive chemicals. Front Neuroeng. 2011;4:4. Epub 2011/05/13. pmid:21562604; PubMed Central PMCID: PMC3087164.
  17. 17. Johnstone AF, Gross GW, Weiss DG, Schroeder OH, Gramowski A, Shafer TJ. Microelectrode arrays: a physiologically based neurotoxicity testing platform for the 21st century. Neurotoxicology. 2010;31:331–50. Epub 2010/04/20. S0161-813X(10)00067-7 [pii]. pmid:20399226.
  18. 18. Gramowski A, Jügelt K, Weiss DG, Gross GW. Substance identification by quantitative characterization of oscillatory activity in murine spinal cord networks on microelectrode arrays. Eur J Neurosci. 2004;19:2815–1825. Epub 2004/05/19. EJN3373 [pii]. pmid:15147315.
  19. 19. Gramowski A, Jügelt K, Stüwe S, Schulze R, McGregor GP, Wartenberg-Demand A, et al. Functional screening of traditional antidepressants with primary cortical neuronal networks grown on multielectrode neurochips. Eur J Neurosci. 2006;24:455–65. Epub 2006/08/15. EJN4892 [pii] pmid:16903853.
  20. 20. Parenti C, Turnaturi R, Arico G, Gramowski-Voss A, Schroeder OH, Marrazzo A, et al. The multitarget opioid ligand LP1's effects in persistent pain and in primary cell neuronal cultures. Neuropharmacology. 2013;71:70–82. Epub 2013/04/02. S0028-3908(13)00104-4 [pii]. pmid:23541722.
  21. 21. Lantz SR, Mack CM, Wallace K, Key EF, Shafer TJ, Casida JE. Glufosinate binds N-methyl-D-aspartate receptors and increases neuronal network activity in vitro. Neurotoxicology. 2014;45:38–47. pmid:25268653.
  22. 22. Hammer H, Bader BM, Ehnert C, Bundgaard C, Bunch L, Hoestgaard-Jensen K, et al. A multifaceted GABAA receptor modulator: Functional properties and molecular mechanism of action of the sedative-hypnotic and recreational drug methaqualone (Quaalude). Mol Pharmacol. 2015;88:401–20. pmid:26056160
  23. 23. Krogsgaard-Larsen P, Johnston GA, Lodge D, Curtis DR. A new class of GABA agonist. Nature. 1977;268(5615):53–5. Epub 1977/07/07. pmid:196200.
  24. 24. Krogsgaard-Larsen P, Mikkelsen H, Jacobsen P, Falch E, Curtis DR, Peet MJ, et al. 4,5,6,7-Tetrahydroisothiazolo[5,4-c]pyridin-3-ol and related analogues of THIP. Synthesis and biological activity. Journal of medicinal chemistry. 1983;26(6):895–900. Epub 1983/06/01. pmid:6304315.
  25. 25. Cotterill E, Hall D, Wallace K, Mundy WR, Eglen SJ, Shafer TJ. Characterization of Early Cortical Neural Network Development in Multiwell Microelectrode Array Plates. J Biomol Screen. 2016;21(5):510–9. pmid:27028607; PubMed Central PMCID: PMCPMC4904353.
  26. 26. van Pelt J, Vajda I, Wolters PS, Corner MA, Ramakers GJ. Dynamics and plasticity in developing neuronal networks in vitro. Progress in brain research. 2005;147:173–88. pmid:15581705.
  27. 27. Chiappalone M, Bove M, Vato A, Tedesco M, Martinoia S. Dissociated cortical networks show spontaneously correlated activity patterns during in vitro development. Brain research. 2006;1093(1):41–53. pmid:16712817.
  28. 28. Chiappalone M, Vato A, Berdondini L, Koudelka-Hep M, Martinoia S. Network dynamics and synchronous activity in cultured cortical neurons. Int J Neural Syst. 2007;17(2):87–103. pmid:17565505.
  29. 29. Gramowski A, Stüwe S, Jügelt K, Schiffmann D, Loock J, Schröder O, et al. Detecting neurotoxicity through electrical activity changes of neuronal networks on multielectrode neurochips. ALTEX. 2006;23:410–5.
  30. 30. Gramowski-Voss A, Schwertle HJ, Pielka AM, Schultz L, Steder A, Jugelt K, et al. Enhancement of Cortical Network Activity in vitro and Promotion of GABAergic Neurogenesis by Stimulation with an Electromagnetic Field with a 150 MHz Carrier Wave Pulsed with an Alternating 10 and 16 Hz Modulation. Front Neurol. 2015;6:158. pmid:26236278; PubMed Central PMCID: PMCPMC4500930.
  31. 31. Klein AB, Bay T, Villumsen IS, Falk-Petersen CB, Marek A, Frolund B, et al. Autoradiographic imaging and quantification of the high-affinity GHB binding sites in rodent brain using 3H-HOCPCA. Neurochemistry international. 2016;100:138–45. 10.1016/j.neuint.2016.09.002. pmid:27615059.
  32. 32. Schmittgen TD, Livak KJ. Analyzing real-time PCR data by the comparative C(T) method. Nat Protoc. 2008;3(6):1101–8. pmid:18546601.
  33. 33. Herculano-Houzel S, Watson C, Paxinos G. Distribution of neurons in functional areas of the mouse cerebral cortex reveals quantitatively different cortical zones. Front Neuroanat. 2013;7:35. pmid:24155697; PubMed Central PMCID: PMCPMC3800983.
  34. 34. Sahara S, Yanagawa Y, O'Leary DD, Stevens CF. The fraction of cortical GABAergic neurons is constant from near the start of cortical neurogenesis to adulthood. J Neurosci. 2012;32(14):4755–61. pmid:22492031; PubMed Central PMCID: PMCPMC3325497.
  35. 35. Schoch S, Cibelli G, Thiel G. Neuron-specific gene expression of synapsin I. Major role of a negative regulatory mechanism. J Biol Chem. 1996;271(6):3317–23. pmid:8621737.
  36. 36. Fritschy JM, Paysan J, Enna A, Mohler H. Switch in the expression of rat GABAA-receptor subtypes during postnatal development: an immunohistochemical study. J Neurosci. 1994;14(9):5302–24. pmid:8083738.
  37. 37. Hornung JP, Fritschy JM. Developmental profile of GABAA-receptors in the marmoset monkey: expression of distinct subtypes in pre- and postnatal brain. J Comp Neurol. 1996;367(3):413–30. pmid:8698901.
  38. 38. Hashimoto T, Nguyen QL, Rotaru D, Keenan T, Arion D, Beneyto M, et al. Protracted developmental trajectories of GABAA receptor alpha1 and alpha2 subunit expression in primate prefrontal cortex. Biol Psychiatry. 2009;65(12):1015–23. pmid:19249749; PubMed Central PMCID: PMCPMC2882199.
  39. 39. Liu Q, Wong-Riley MT. Developmental changes in the expression of GABAA receptor subunits alpha1, alpha2, and alpha3 in the rat pre-Botzinger complex. J Appl Physiol (1985). 2004;96(5):1825–31. pmid:14729731.
  40. 40. Ebert B, Thompson SA, Saounatsou K, McKernan R, Krogsgaard-Larsen P, Wafford KA. Differences in agonist/antagonist binding affinity and receptor transduction using recombinant human γ-aminobutyric acid type A receptors. Mol Pharmacol. 1997;52:1150–6. Epub 1997/12/16. pmid:9396785.
  41. 41. Harris RA, Mihic SJ, Brozowski S, Hadingham K, Whiting PJ. Ethanol, flunitrazepam, and pentobarbital modulation of GABAA receptors expressed in mammalian cells and Xenopus oocytes. Alcohol Clin Exp Res. 1997;21(3):444–51. pmid:9161604.
  42. 42. Storustovu SI, Ebert B. Pharmacological characterization of agonists at δ-containing GABAA receptors: Functional selectivity for extrasynaptic receptors is dependent on the absence of γ2. J Pharmacol Exp Ther. 2006;316:1351–9. pmid:16272218.
  43. 43. Kaupmann K, Malitschek B, Schuler V, Heid J, Froestl W, Beck P, et al. GABAB-receptor subtypes assemble into functional heteromeric complexes. Nature. 1998;396:683–6. pmid:9872317
  44. 44. Bräuner-Osborne H, Krogsgaard-Larsen P. Functional pharmacology of cloned heterodimeric GABAB receptors expressed in mammalian cells. BrJPharmacol. 1999;128:1370–4.
  45. 45. Wise A, Green A, Main MJ, Wilson R, Fraser N, Marshall F. Calcium sensing properties of the GABAB receptor. Neuropharmacology. 1999;38:1647–56. pmid:10587080
  46. 46. Sieghart W. Allosteric modulation of GABAA receptors via multiple drug-binding sites. Adv Pharmacol. 2015;72:53–96. pmid:25600367
  47. 47. Rabe H, Kronbach C, Rundfeldt C, Luddens H. The novel anxiolytic ELB139 displays selectivity to recombinant GABAA receptors different from diazepam. Neuropharmacology. 2007;52:796–801. Epub 2006/11/08. S0028-3908(06)00339-X [pii] pmid:17087982.
  48. 48. Wafford KA, Whiting PJ, Kemp JA. Differences in affinity and efficacy of benzodiazepine receptor ligands at recombinant gamma-aminobutyric acidA receptor subtypes. Mol Pharmacol. 1993;43(2):240–4. pmid:8381510.
  49. 49. Hammer H, Ebert B, Jensen HS, Jensen AA. Functional characterization of the 1,5-benzodiazepine clobazam and its major active metabolite N-desmethylclobazam at human GABAA receptors expressed in Xenopus laevis oocytes. PLoS ONE. 2015;10:e0120239. pmid:25798598
  50. 50. Baur R, Sigel E. Replacement of histidine in position 105 in the alpha5 subunit by cysteine stimulates zolpidem sensitivity of alpha5beta2gamma2 GABAA receptors. J Neurochem. 2007;103(6):2556–64. pmid:17953656.
  51. 51. Sanna E, Busonero F, Talani G, Carta M, Massa F, Peis M, et al. Comparison of the effects of zaleplon, zolpidem, and triazolam at various GABAA receptor subtypes. European journal of pharmacology. 2002;451:103–10. Epub 2002/09/17. S001429990202191X [pii]. pmid:12231378.
  52. 52. Casula MA, Bromidge FA, Pillai GV, Wingrove PB, Martin K, Maubach K, et al. Identification of amino acid residues responsible for the alpha5 subunit binding selectivity of L-655,708, a benzodiazepine binding site ligand at the GABAA receptor. Journal of neurochemistry. 2001;77:445–51. pmid:11299307.
  53. 53. Meera P, Wallner M, Otis TS. Molecular basis for the high THIP/gaboxadol sensitivity of extrasynaptic GABAA receptors. Journal of neurophysiology. 2011;106:2057–64. Epub 2011/07/29. [pii]. pmid:21795619; PubMed Central PMCID: PMC3191842.
  54. 54. Ahring PK, Bang LH, Jensen ML, Strøbæk D, Hartiadi LY, Chebib M, et al. A pharmacological assessment of agonists and modulators at alpha4beta2gamma2 and alpha4beta2delta GABAA receptors: The challenge in comparing apples with oranges. Pharmacol Res. 2016;111:563–76. pmid:27178730.
  55. 55. Mortensen M, Ebert B, Wafford K, Smart TG. Distinct activities of GABA agonists at synaptic- and extrasynaptic-type GABAA receptors. The Journal of physiology. 2010;588(Pt 8):1251–68. Epub 2010/02/24. jphysiol.2009.182444 [pii] pmid:20176630.
  56. 56. Krogsgaard-Larsen P, Frølund B, Liljefors T, Ebert B. GABAA agonists and partial agonists: THIP (Gaboxadol) as a non-opioid analgesic and a novel type of hypnotic. Biochem Pharmacol. 2004;68:1573–80. Epub 2004/09/29. S0006-2952(04)00537-4 [pii]. pmid:15451401.
  57. 57. Hoestgaard-Jensen K, Dalby NO, Krall J, Hammer H, Krogsgaard-Larsen P, Frølund B, et al. Probing α4βδ GABAA receptor heterogeneity: differential regional effects of a functionally selective α4β1δ/α4β3δ receptor agonist on tonic and phasic inhibition in rat brain. J Neurosci. 2014;34:16256–72 pmid:25471566
  58. 58. Chandra D, Jia F, Liang J, Peng Z, Suryanarayanan A, Werner DF, et al. GABAA receptor α4 subunits mediate extrasynaptic inhibition in thalamus and dentate gyrus and the action of gaboxadol. Proc Natl Acad Sci USA. 2006;103:15230–5. Epub 2006/09/29. 0604304103 [pii] pmid:17005728; PubMed Central PMCID: PMC1578762.
  59. 59. Belelli D, Peden DR, Rosahl TW, Wafford KA, Lambert JJ. Extrasynaptic GABAA receptors of thalamocortical neurons: a molecular target for hypnotics. J Neurosci. 2005;25:11513–20. Epub 2005/12/16. 25/50/11513 [pii] pmid:16354909.
  60. 60. Herd MB, Haythornthwaite AR, Rosahl TW, Wafford KA, Homanics GE, Lambert JJ, et al. The expression of GABAA beta subunit isoforms in synaptic and extrasynaptic receptor populations of mouse dentate gyrus granule cells. J Physiol. 2008;586(4):989–1004. pmid:18079158; PubMed Central PMCID: PMC2375644.
  61. 61. Wafford KA, van Niel MB, Mab QP, Horridge E, Herd MB, Peden DR, et al. Novel compounds selectively enhance δ subunit containing GABAA receptors and increase tonic currents in thalamus. Neuropharmacology. 2009;56:182–9. pmid:18762200
  62. 62. Jensen ML, Wafford KA, Brown AR, Belelli D, Lambert JJ, Mirza NR. A study of subunit selectivity, mechanism and site of action of the δ selective compound 2 (DS2) at human recombinant and rodent native GABAA receptors. Br J Pharmacol. 2013;168:1118–32. Epub 2012/10/16. pmid:23061935; PubMed Central PMCID: PMC3594672.
  63. 63. Barrera NP, Betts J, You H, Henderson RM, Martin IL, Dunn SM, et al. Atomic force microscopy reveals the stoichiometry and subunit arrangement of the α4β3δ GABAA receptor. Mol Pharmacol. 2008;73(3):960–7. pmid:18079275.
  64. 64. Eaton M, Bracamontes J, Shu HJ, Li P, Mennerick SJ, Steinbach JH, et al. GABAA α4, β2 and δ subunits assemble to produce more than one functionally distinct receptor type. Mol Pharmacol. 2014;86:647–56. pmid:25238745
  65. 65. Shu HJ, Bracamontes J, Taylor A, Wu K, Eaton MM, Akk G, et al. Characteristics of concatemeric GABAA receptors containing α4/δ subunits expressed in Xenopus oocytes. Br J Pharmacol. 2012;165:2228–43. pmid:21950777; PubMed Central PMCID: PMC3413859.
  66. 66. Patel B, Mortensen M, Smart TG. Stoichiometry of δ subunit containing GABAA receptors. Br J Pharmacol. 2014;171(4):985–94. Epub 2013/11/12. pmid:24206220; PubMed Central PMCID: PMC3925037.
  67. 67. Wagoner KR, Czajkowski C. Stoichiometry of expressed a4b2d g-aminobutyric acid type A receptors depends on the ratio of subunit cDNA transfected. J Biol Chem. 2010;285(19):14187–94. pmid:20233712; PubMed Central PMCID: PMCPMC2863200.
  68. 68. Mortensen M, Smart TG. Extrasynaptic αβ subunit GABAA receptors on rat hippocampal pyramidal neurons. J Physiol. 2006;577:841–56. Epub 2006/10/07. jphysiol.2006.117952 [pii] pmid:17023503; PubMed Central PMCID: PMC1890388.
  69. 69. Milenkovic I, Vasiljevic M, Maurer D, Hoger H, Klausberger T, Sieghart W. The parvalbumin-positive interneurons in the mouse dentate gyrus express GABA receptor subunits alpha1, beta2, and delta along their extrasynaptic cell membrane. Neuroscience. 2013;254C:80–96. Epub 2013/09/24. S0306-4522(13)00791-4 [pii] pmid:24055402.
  70. 70. Marowsky A, Rudolph U, Fritschy JM, Arand M. Tonic inhibition in principal cells of the amygdala: a central role for α3 subunit-containing GABAA receptors. J Neurosci. 2012;32(25):8611–9. Epub 2012/06/23. [pii]. pmid:22723702.
  71. 71. Yamada J, Furukawa T, Ueno S, Yamamoto S, Fukuda A. Molecular basis for the GABAA receptor-mediated tonic inhibition in rat somatosensory cortex. Cereb Cortex. 2007;17(8):1782–7. pmid:16997904.
  72. 72. Wisden W, Cope D, Klausberger T, Hauer B, Sinkkonen ST, Tretter V, et al. Ectopic expression of the GABAA receptor alpha6 subunit in hippocampal pyramidal neurons produces extrasynaptic receptors and an increased tonic inhibition. Neuropharmacology. 2002;43(4):530–49. pmid:12367600.
  73. 73. Wu X, Huang L, Wu Z, Zhang C, Jiang D, Bai Y, et al. Homeostatic competition between phasic and tonic inhibition. J Biol Chem. 2013;288(35):25053–65. pmid:23839941; PubMed Central PMCID: PMCPMC3757170.
  74. 74. Comenencia-Ortiz E, Moss SJ, Davies PA. Phosphorylation of GABAA receptors influences receptor trafficking and neurosteroid actions. Psychopharmacology. 2014;231(17):3453–65. pmid:24847959; PubMed Central PMCID: PMC4135009.